Antipsychotic drugs and risk of type 2 diabetes: An evidence-based approach

Human Psychopharmacology

Volumn 19, Issue 8, 2004, Pages 549-558

  Bellantuono, Cesario ^a   Tentoni, Luigi ^a   Donda, Pietro ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b Eli Lilly Italia ^*  (Italy)

Author keywords

Antipsychotic drugs; Clozapine; Olanzapine; Quetiapine; Risperidone; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; CLOZAPINE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; INSULIN; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE;

CLINICAL TRIAL; COMORBIDITY; DRUG EXPOSURE; EVIDENCE BASED MEDICINE; HUMAN; INCIDENCE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BIAS (EPIDEMIOLOGY); CROSS-SECTIONAL STUDIES; DATA COLLECTION; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK; SCHIZOPHRENIA;

EID: 11144318853     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.628     Document Type: Review

References (60)

1. American Diabetes Association. 1999. National Standards for Diabetes Self-Management and American Diabetes Association Review Criteria. Diabetes Care 22: S111-S114.
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. 2004. Diabetes Care 27: 596-601.
3. American Diabetes Association. Accessed December 10, 2001. ADA Website: Impact of diabetes. Available at: http://www.diabetes.org:80/main/application/ commercewf?origin=*.jsp&event=link(B1_1)
4. Arneson GA. 1964. Phenothiazine derivatives and glucose metabolism. J Neuropsychiatry 5: 181-185.
5. Balter AM. 1961. Glucose tolerance curves in neuropsychiatric patients. Diabetes 10: 100-104.
6. Biswasl PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA. 2001. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 15: 265-271.
7. Braceland FJ, Meduna LJ, Vaichulis JA. 1945. Delayed action of insulin in schizophrenia. Am J Psychiatry 102: 108-110.
8. Buse JB. 2002. Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. J Clin Psychiatry 63: 37-41.
9. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. 2003. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56: 164-170.
10. Bushe C, Holt R. 2004. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry 184: S67-S71.
11. Caro JJ, Ward A, Levinton C, Robinson K. 2002. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63: 1135-1139.
12. Chae BJ, Kang BJ. 2001. The effect of clozapine on blood glucose metabolism. Hum Psychopharmacol 16: 265-271
13. Charatan FBE, Bartiett NG. 1955. The effect of chlorpromazine ('Largactil') on glucose tolerance. J Ment Sci 101: 351-353.
14. Cheta D, Dumitrescu C, Georgescu M, et al. 1990. A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabetes Metab 16: 11-15.
15. Dinan TG, Kohen D. 2003. Atypical antipsychotics and diabetic propensity: more questions than answers? Hum Psychopharmacol 18 591-593.
16. Dixon L, Weiden P, Delahanty J, et al. 2000. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26: 903-912.
17. Expert Group. 2004. 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry 184: S112-S114.
18. Finney GOH. 1989. Juvenile onset diabetes and schizophrenia? Lancet 2: 1214-1215.
19. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. 2002. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63: 920-930.
20. Haddad PM. 2004. Antipsychotics and diabetes: review of non-prospective data. Br J Psychiatry 184: 80-86.
21. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. 1998. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 59 294-299.
22. Harris MI, Flegal KM, Cowie CC, et al. 1998. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21: 518-524.
23. Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O. 2002. Glucose intolerance with atypical antipsychotics: Drug Saf 25 1107-1116.
24. Henderson DC, Cagliero E, Gray C, et al. 2000. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157: 975-981.
25. Hiles BW. 1956. Hyperglycemia and glycosuria following chlorpromazine therapy. JAMA 126: 1651.
26. Kasanin J. 1926. The blood sugar curve in mental disease. Arch Neurol Psychiatry 16: 414-419.
27. Keskiner A, El Toumi A, Bousquet T. 1973. Psychotropic drugs, diabetes, and chronic mental patients. Dis Nerv Syst 14: 176-181.
28. Kohen D. 2004. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 47: S64-S66.
29. Koller E, Schneider B, Bennett K, Dubitsky G. 2001. Clozapine-associated diabetes. Am J Med 111: 716-723.
30. Koller EA, Doraiswamy PM. 2002. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22: 841-852.
31. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. 2003. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 23: 735-744.
32. Koller EA, Weber J, Doraiswamy PM, Schneider BS. 2004. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 65: 857-863.
33. Kooy FH. 1919. Hyperglycemia in mental disorders. Brain 42: 214-288.
34. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. 2002. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 63: 758-762.
35. Koro CE, Fedder DO, L'Italien GJ, et al. 2002. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 325: 243.
36. Lamberti J, Crilly J, Maharaj K, et al. 2003. Prevalence of adult-onset diabetes among outpatients receiving antipsychotic drugs. Int Cong Schizophrenia Res 60: 360.
37. Leonard P, Halley A, Browne S. 2002. Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine. Irish Med J 95: 119-120.
38. Lindenmayer JP, Czobor P, Volavka J, et al. 2003. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160: 290-296.
39. Lindenmayer JP, Nathan AM, Smith RC. 2001. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 62(Suppl. 23): 30-38.
40. Lorenz WF. 1922. Sugar tolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 8: 184-196.
41. Lund BC, Perry PJ, Brooks JM, Arndt S. 2001. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 58 1172-1176.
42. Melkersson KI, Hulting AL, Brismar KE. 1999. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 60: 783-791.
43. Melkersson KI, Hulting AL, Brismar KE. 2000. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61: 742-749.
44. Meyer JM. 2002. A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated impatients: metabolic outcomes after 4 years. J Clin Psychiatry 63: 425-433.
45. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. 1996. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37: 68-73.
46. National Diabetes Data Group. 1979. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039-1057.
47. Newcomer JW, Haupt DW, Fucetola R, et al. 2002. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59: 337-345.
48. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. 2002. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 70: 19-26.
49. Ryan MC, Collins P, Thacore JH. 2003. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284-289.
50. Schwarz L, Munoz R. 1968. Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry 125: 253-255.
51. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. 2002. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159: 561-566.
52. Subramaniam M, Chong SA, Pek E. 2003. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 48: 345-347.
53. Tabata H, Kikuoka M, Kikuoka H, et al. 1987. Characteristics of diabetes mellitus in schizophrenic patients. J Med Assoc Thai 70: 90-93.
54. Thonnard-Neumann E. 1956. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 29: 827-828.
55. Thonnard-Neumann E. 1968. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 124: 978-982.
56. Walley T, Mantgani A. 1997. The UK General Practice Research Database. Lancet 50: 1097-1099.
57. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. 2002. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 22: 236-243.
58. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. 2002. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63: 856-865.
59. World Health Organization Expert Committee on Diabetes Mellitus. 1980. Second report. WHO Tech Rep Ser 646.
60. World Health Organization: http://www.who.int/ncd/dia/databases.htm, accessed on December 2002.